New diabetic drug takes you to the “Journey from fat to fit”

 “People with high blood pressure, diabetes- those conditions are brought about by life style. If you change the life style, those conditions will leave”. Diabetes is caused mainly due to the failure of body in producing enough amount of insulin. There are two types of diabetes: type 1 diabetes and type 2 diabetes. Type 2 diabetes is more prevalent and is therefore found in all age groups including children and adolescents. Diabetes becomes the major cause of blindness, non-traumatic lower extremity amputations, and end stage kidney diseases. People with diabetics are more prone to have cardiovascular diseases than those with no diabetes. There are 30.3 million people in the US alone living with the diabetes, accounting for 9.4% of the US population. Type 2 diabetes is preventable and studies suggest that changes in lifestyle and reduction in weight with a small amount in the range of 5%-10% can prevent type 2 diabetes among high-risk adults. People with type 2 diabetes are mostly overweight or obese. Significant reduction in the weight of diabetics usually help them in the reduction of blood sugar to better control diabetes.

For more details visit: https://www.omrglobal.com/industry-reports/diabetes-market/

“Laughter is the best medicine-unless you are diabetic, then insulin comes pretty high on the list”. Insulin becomes the top most priority for diabetics in terms of medication. When the diabetic drug helps in weight loss management and provide cardiovascular benefits, it is like the “icing on the cake”. The newest diabetic drug, Ozempic (semaglutide) offered by Novo Nordisk has been approved by the FDA in December 2017. This drug was available in the US market in the first three months of 2018. It is a -weekly injection that has been clinically proved to reduce A1C levels along with weight in clinical trials. Ozempic benefits the adults living with type 2 diabetes with improved glycemic control with a weekly dosing schedule. During the process of FDA approval in clinical trials, one concern that comes up was the slightly high rate of retinopathy or eye damage observed in the Ozempic users. The Ozempic users who have experienced retinopathy was 3% that is comparable to 1.8% of the people taking placebo. This concern was addressed by the FDA by including a warning on the Ozempic’s label. This warning is mainly relevant to the people with some history of retinopathy prior to taking Ozempic.

More facts to know about Ozempic

Ozempic is a GLP-1 receptor agonist. It is the third approved weekly drug by the FDA and seventh approved drug in the US market. This drug works by simulating the insulin production of the body and reduces appetite. Two doses of 0.5 mg and 1 mg are approved and are to be delivered from pre-filled pens. The drug was tested in clinical study of 1200 type 2 diabetics and found significant loss in weight of the patients taking this drug. Over 56 weeks, patients taking lower dose of the drug were able to reduce an average weight of 9.5 pounds or 4.3 kilograms, and those taking higher dose were able to lose 13.5 pounds or 6.1 kilograms. It is comparable to the patients taking Januvia drug, who were able to reduce an average of just 4 pounds or 1.9 kilograms. Ozempic will now be competing with other popular once-weekly drugs in the market such as Trulicity (dulaglutide) by Eli Lilly and Co., and Bydureon (exenatide) by AstraZeneca PLC. There is another competing drug, Tanzeum (albiglutide) which is soon to be discontinued. In a one-on-one trial against Trulicity, Ozempic showed better results with 1.8% A1C reduction as compared to 1.4% by Trulicity and double the weight loss (10-14 pounds by Ozempic versus 5-7 pounds by Trulicity). In the clinical trials, it was even observed that Ozempic could reduce the risks of stroke, heart attack, and fatality due to cardiovascular diseases.

For More update Follow: LinkedIn

CONTACT US

Orion Market Research Pvt Ltd
116, Shagun Arcade
Vijay Nagar Square
Indore, Madhya Pradesh- India - 452010
India: +91-780-304-0404
Global:+1-646-755-7667
Email: info@omrglobal.com, support@omrglobal.com
Website: https://www.omrglobal.com
Blog: https://omrglobalblog.wordpress.com